624733-88-6

MK-0812 is administered by continuous i.v. infusion to maintain a constant level of the drug in blood^[1]. Administration of MK0812 at 30 mg/kg, p.o. reduces the frequency of Ly6G^-Ly6C^hi monocytes in the peripheral blood, while no impact on circulating Ly6G⁺Ly6C⁺ neutrophil frequency is observed. In addition, MK0812 treatment causes a dose-dependent reduction in circulating Ly6C^hi monocytes and a corresponding elevation in the CCR2 ligand CCL2^[2].